<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02751359</url>
  </required_header>
  <id_info>
    <org_study_id>7009</org_study_id>
    <nct_id>NCT02751359</nct_id>
  </id_info>
  <brief_title>Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers</brief_title>
  <official_title>Characterization of the Analgesic Effects of Oral CBD in Healthy, Normal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double-blind, placebo-controlled study is to determine the analgesic&#xD;
      effects of cannabidiol (CBD), a chemical constituent found in cannabis that does not have&#xD;
      intoxicating effects. The analgesic effects of CBD will be assessed using the Cold-Pressor&#xD;
      Test (CPT), a laboratory model of pain which has predictive validity for the clinical use of&#xD;
      analgesics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This within-subject, double-blind, placebo-controlled study will assess the analgesic and&#xD;
      subjective effects of a range of CBD doses (0, 200, 400, or 800 mg, po). Volunteers will&#xD;
      participate in 4 outpatient laboratory sessions over the course of 4 weeks during which the&#xD;
      analgesic effects of CBD will be assessed using the Cold-Pressor Test (CPT), a laboratory&#xD;
      model of pain which has predictive validity for the clinical use of analgesics. The order of&#xD;
      CBD dose will be randomized across participants. Secondary measures will include subjective&#xD;
      and physiologic effects of CBD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test</measure>
    <time_frame>Baseline, 60 minutes, 120 minutes 180 minutes, 240 minutes, 300 minutes and 360 minutes after each dose</time_frame>
    <description>Time to first feel pain (&quot;Pain threshold&quot; measured in seconds) during the Cold Pressor Test and withdraw the hand from the cold water (&quot;Pain Tolerance&quot; measured in seconds). Changes in threshold from baseline were averaged across study sessions for each CBD dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Drug Effects Related to Abuse Liability as Measured by Visual Analog Scales</measure>
    <time_frame>30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, 270 minutes, 300 minutes, 330 minutes, 360 minutes</time_frame>
    <description>Participants rate the strength of their desire to take again, drug liking, good effect and bad effect. Each item was presented and the participant was asked to rate his / her rating on a scale anchored by 'Not At All' (0 mm) to 'Extremely' (100 mm). The average of all timepoints is reported for each category.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Active CBD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>200, 400, or 800 mg Cannabidiol</description>
    <arm_group_label>Active CBD</arm_group_label>
    <other_name>CBD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg Cannabidiol</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to perform study procedures&#xD;
&#xD;
          -  Women practicing an effective form of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are currently pregnant or breastfeeding.&#xD;
&#xD;
          -  Current illicit drug use&#xD;
&#xD;
          -  Presence of significant medical illness&#xD;
&#xD;
          -  History of heart disease&#xD;
&#xD;
          -  Request for drug treatment&#xD;
&#xD;
          -  Current parole or probation&#xD;
&#xD;
          -  Recent history of significant violent behavior&#xD;
&#xD;
          -  Major psychiatric disorder&#xD;
&#xD;
          -  Current use of any prescription or over-the-counter medication&#xD;
&#xD;
          -  Current pain&#xD;
&#xD;
          -  Clinically significant Raynaud's syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziva D Cooper, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute / CUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cooper</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <results_first_submitted>April 19, 2021</results_first_submitted>
  <results_first_submitted_qc>April 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2021</results_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Ziva D. Cooper, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Neurobiology (in Psychiatry)</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 23, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT02751359/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Group - Repeated Measures</title>
          <description>Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study day; on 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographics were collected for study completers</population>
      <group_list>
        <group group_id="B1">
          <title>Single Group - Repeated Measures</title>
          <description>Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study day; on 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test</title>
        <description>Time to first feel pain (&quot;Pain threshold&quot; measured in seconds) during the Cold Pressor Test and withdraw the hand from the cold water (&quot;Pain Tolerance&quot; measured in seconds). Changes in threshold from baseline were averaged across study sessions for each CBD dose.</description>
        <time_frame>Baseline, 60 minutes, 120 minutes 180 minutes, 240 minutes, 300 minutes and 360 minutes after each dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active CBD 200 mg</title>
            <description>Cannabidiol: 200mg</description>
          </group>
          <group group_id="O2">
            <title>Active CBD 400 mg</title>
            <description>Cannabidiol: 400mg</description>
          </group>
          <group group_id="O3">
            <title>Active CBD 800 mg</title>
            <description>Cannabidiol: 800mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)&#xD;
Placebo: 0 mg Cannabidiol</description>
          </group>
        </group_list>
        <measure>
          <title>Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test</title>
          <description>Time to first feel pain (&quot;Pain threshold&quot; measured in seconds) during the Cold Pressor Test and withdraw the hand from the cold water (&quot;Pain Tolerance&quot; measured in seconds). Changes in threshold from baseline were averaged across study sessions for each CBD dose.</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="7.0"/>
                    <measurement group_id="O2" value="2.2" spread="0.8"/>
                    <measurement group_id="O3" value="2.1" spread="2.4"/>
                    <measurement group_id="O4" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tolerance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="5.3"/>
                    <measurement group_id="O2" value="15.3" spread="8.0"/>
                    <measurement group_id="O3" value="-0.6" spread="0.9"/>
                    <measurement group_id="O4" value="9.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Drug Effects Related to Abuse Liability as Measured by Visual Analog Scales</title>
        <description>Participants rate the strength of their desire to take again, drug liking, good effect and bad effect. Each item was presented and the participant was asked to rate his / her rating on a scale anchored by 'Not At All' (0 mm) to 'Extremely' (100 mm). The average of all timepoints is reported for each category.</description>
        <time_frame>30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, 210 minutes, 270 minutes, 300 minutes, 330 minutes, 360 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active CBD 200 mg</title>
            <description>Cannabidiol: 200mg</description>
          </group>
          <group group_id="O2">
            <title>Active CBD 400 mg</title>
            <description>Cannabidiol: 400mg</description>
          </group>
          <group group_id="O3">
            <title>Active CBD 800 mg</title>
            <description>Cannabidiol: 800mg</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)&#xD;
Placebo: 0 mg Cannabidiol</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Drug Effects Related to Abuse Liability as Measured by Visual Analog Scales</title>
          <description>Participants rate the strength of their desire to take again, drug liking, good effect and bad effect. Each item was presented and the participant was asked to rate his / her rating on a scale anchored by 'Not At All' (0 mm) to 'Extremely' (100 mm). The average of all timepoints is reported for each category.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="3.8"/>
                    <measurement group_id="O2" value="19.0" spread="5.9"/>
                    <measurement group_id="O3" value="10.2" spread="4.7"/>
                    <measurement group_id="O4" value="13.3" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad effect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="3.5"/>
                    <measurement group_id="O2" value="9.1" spread="4.4"/>
                    <measurement group_id="O3" value="4.5" spread="2.2"/>
                    <measurement group_id="O4" value="4.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug liking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="5.2"/>
                    <measurement group_id="O2" value="21.3" spread="5.7"/>
                    <measurement group_id="O3" value="15.8" spread="5.1"/>
                    <measurement group_id="O4" value="18.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Desire to take again</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9" spread="5.7"/>
                    <measurement group_id="O2" value="23.6" spread="6.6"/>
                    <measurement group_id="O3" value="18.1" spread="5.9"/>
                    <measurement group_id="O4" value="17.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During and after each study session, average of 4 weeks total study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active CBD 200 mg</title>
          <description>Cannabidiol: 200mg</description>
        </group>
        <group group_id="E2">
          <title>Active CBD 400 mg</title>
          <description>Cannabidiol: 400mg</description>
        </group>
        <group group_id="E3">
          <title>Active CBD 800 mg</title>
          <description>Cannabidiol: 800mg</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)&#xD;
Placebo: 0 mg Cannabidiol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gas and cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Subtle mood change</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Wooziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent urination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ziva Cooper, Principal Investigator</name_or_title>
      <organization>University of California Los Angeles</organization>
      <phone>310-206-9942</phone>
      <email>zcooper@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

